Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER GALLAGHER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1467430579
CMS profile
1059838
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$30,914.33

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER GALLAGHER

NPI 1467430579 · CMS profile ID 1059838

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467430579?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER GALLAGHER, NPI 1467430579, CMS profile ID 1059838. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467430579?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHRISTOPHER GALLAGHER, NPI 1467430579, CMS profile ID 1059838. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467430579?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHRISTOPHER GALLAGHER, NPI 1467430579, CMS profile ID 1059838, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1467430579?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $30,914.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $78.7311/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006584443 CMS
Daiichi Sankyo Inc. $4,100.0011/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006584625 CMS
Daiichi Sankyo Inc. $103.8811/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006588601 CMS
Daiichi Sankyo Inc. $4,100.0011/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006583891 CMS
Daiichi Sankyo Inc. $1,027.5011/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006613045 CMS
Daiichi Sankyo Inc. $37.7311/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006583989 CMS
Daiichi Sankyo Inc. $123.9611/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006589099 CMS
Daiichi Sankyo Inc. $18.5410/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006528099 CMS
Pharmacyclics LLC, An AbbVie Company $31.9910/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998285793 CMS
Lilly USA, LLC $7,200.0008/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031338305 CMS
PFIZER INC. $25.8007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050596333 CMS
PFIZER INC. $2.7007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049553175 CMS
Stemline Therapeutics Inc. $30.7806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040023365 CMS
E.R. Squibb & Sons, L.L.C. $36.8705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015551657 CMS
AstraZeneca Pharmaceuticals LP $2,055.0005/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015980681 CMS
SERVIER PHARMACEUTICALS LLC $24.0305/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055086239 CMS
PFIZER INC. $1,250.0005/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130864934 CMS
PFIZER INC. $20.5703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050701405 CMS
Daiichi Sankyo Inc. $12.4503/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006592104 CMS
Daiichi Sankyo Inc. $2,750.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006586479 CMS
Daiichi Sankyo Inc. $100.8003/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006592343 CMS
Stemline Therapeutics Inc. $2,160.0002/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040023359 CMS
PFIZER INC. $2,198.0001/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130864936 CMS
AstraZeneca Pharmaceuticals LP $685.0001/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011726215 CMS
AstraZeneca Pharmaceuticals LP $2,740.0001/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015341593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,596.91 4
PY2020 $11,770.55 12
PY2021 $14,659.83 14
PY2022 $32,572.39 26
PY2023 $30,914.33 25
PY2024 $12,283.14 19
PY2025 $3,812.19 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $134,677.68 26
PY2024 Principal investigator $192,960.63 22
PY2023 Recipient $109.20 1
PY2023 Principal investigator $287,719.82 33
PY2022 Principal investigator $223,087.49 47
PY2021 Recipient $2,220.00 4
PY2021 Principal investigator $184,110.05 25
PY2020 Principal investigator $291,681.40 53
PY2019 Principal investigator $138,556.60 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $11.76 12/31/2022 Non-covered Recipient Entity
WASHINGTON CANCER INSTITUTE AT MEDSTAR WASHINGTON HOSPITAL CENTER
A Phase II Clinical Trial of Pembrolizumab MK-3475 as Monotherapy for Metastatic Triple Negative Breast Cancer mTNBC KEYNOTE-086 No dispute reported 06/30/2026 940404577
Principal investigator 1 G1 Therapeutics, Inc. $500.00 11/14/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581587
Principal investigator 1 Daiichi Sankyo Inc. $500.00 10/05/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935023847
Principal investigator 1 G1 Therapeutics, Inc. $26,509.28 09/28/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581575
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 09/21/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021766
Principal investigator 1 Daiichi Sankyo Inc. $9,250.00 09/21/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021859
Principal investigator 1 MacroGenics, Inc. $2,992.86 09/19/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936959533
Principal investigator 1 Daiichi Sankyo Inc. $500.00 09/16/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935020697
Principal investigator 1 MacroGenics, Inc. $2,124.20 09/15/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936959451
Principal investigator 1 G1 Therapeutics, Inc. $500.00 09/14/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581585
Principal investigator 1 Daiichi Sankyo Inc. $500.00 09/09/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935020593
Principal investigator 1 Daiichi Sankyo Inc. $21,150.00 09/09/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021453
Principal investigator 1 Daiichi Sankyo Inc. $21,150.00 09/02/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935021315
Principal investigator 1 MacroGenics, Inc. $2,297.50 08/25/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936959043
Principal investigator 1 Daiichi Sankyo Inc. $650.00 08/15/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021096
Principal investigator 1 Daiichi Sankyo Inc. $7,000.00 08/15/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021657
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 08/15/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935021705
Principal investigator 1 G1 Therapeutics, Inc. $32,345.88 07/28/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581573
Principal investigator 1 Daiichi Sankyo Inc. $500.00 06/24/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935018675
Principal investigator 1 Daiichi Sankyo Inc. $9,250.00 06/24/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935019525
Principal investigator 1 G1 Therapeutics, Inc. $7,068.00 06/14/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581577
Principal investigator 1 PFIZER INC. $7,177.00 06/04/2022 Non-covered Recipient Entity
MedStar Health Research Institute Inc
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 949784411
Principal investigator 1 MacroGenics, Inc. $3,000.00 05/26/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936957819
Principal investigator 1 Daiichi Sankyo Inc. $2,175.00 05/25/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935018149
Principal investigator 1 Daiichi Sankyo Inc. $650.00 05/25/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935018241
Principal investigator 1 Daiichi Sankyo Inc. $845.00 05/25/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935019429
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 05/25/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935019603
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 05/25/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935019808
Principal investigator 1 G1 Therapeutics, Inc. $4,991.87 05/19/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581583
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/13/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U301 No dispute reported 06/30/2026 935018235
Principal investigator 1 MacroGenics, Inc. $3,273.50 04/25/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936957313
Principal investigator 1 G1 Therapeutics, Inc. $500.00 03/17/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581589
Principal investigator 1 Daiichi Sankyo Inc. $195.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016613
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016619
Principal investigator 1 Daiichi Sankyo Inc. $2,600.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016625
Principal investigator 1 Daiichi Sankyo Inc. $845.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016629
Principal investigator 1 Daiichi Sankyo Inc. $4,203.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016635
Principal investigator 1 Daiichi Sankyo Inc. $500.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016657
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 03/04/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016671
Principal investigator 1 Genentech, Inc. $10,939.16 02/25/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
PERJETA SAFETY STUDY IN NEO ADJUVANT BC No dispute reported 06/30/2026 950682603
Principal investigator 1 Daiichi Sankyo Inc. $7,000.00 02/18/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016317
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 02/18/2022 Non-covered Recipient Entity
Medstar Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 935016329
Principal investigator 1 G1 Therapeutics, Inc. $6,124.00 02/14/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581581
Principal investigator 1 G1 Therapeutics, Inc. $6,999.98 02/10/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581579
Principal investigator 1 Genentech, Inc. $58.50 01/28/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB No dispute reported 06/30/2026 950685815
Principal investigator 1 G1 Therapeutics, Inc. $5,818.00 01/13/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) No dispute reported 06/30/2026 945581591
Principal investigator 1 MacroGenics, Inc. $1,593.00 01/10/2022 Non-covered Recipient Entity
MEDSTAR HEALTH RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT No dispute reported 06/30/2026 936955379